GlassScriptPhysician profile
Gregory J Bezanis
NPI 1952395436
$11,162.90
in general payments reported to CMS, 2019-2025
23 companies · $3,405 in 2025
The $3,405 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $155 · 2021: $1,051 · 2022: $2,704 · 2023: $1,601 · 2024: $1,819 · 2025: $3,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,513 · Consulting Fee: $2,100 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,513.38 |
| Consulting Fee | $2,100.00 |
| Education | $211.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,400.24 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $2,587.64 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $2,560.77 | 2019-2025 | |
| Ucb, INC. | $495.32 | 2023-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $326.88 | 2019-2024 | Winlevi, Ilumya |
| Arcutis Biotherapeutics, INC. | $233.36 | 2023 | |
| Dermavant Sciences, INC. | $229.62 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $215.61 | 2021-2025 | Aklief |
| Pfizer INC. | $194.84 | 2019-2025 | |
| Genzyme Corporation | $169.93 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $151.99 | 2022-2024 | |
| Incyte Corporation | $131.93 | 2021-2025 | Opzelura |
| Amgen INC. | $117.96 | 2020-2025 | Otezla, Otezla |
| Sandoz INC. | $67.36 | 2024 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $61.73 | 2019-2025 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $54.49 | 2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.24 | 2021 | |
| Strata Skin Sciences, INC. | $33.07 | 2019 | |
| Blueprint Medicines Corporation | $25.43 | 2024 | Ayvakit |
| Almirall LLC | $22.32 | 2019 | |
| Encore Dermatology INC. | $19.04 | 2019 | |
| Lilly USA, LLC | $17.62 | 2021 | |
| Organon LLC | $12.51 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Bezanis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.